吉西他滨、奥沙利铂及抗CD20疗法在不适于强化治疗的儿童和青少年非霍奇金淋巴瘤中的应用。

Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.

作者信息

Bender Jonathan D, Rubinstein Jeremy D, Mizukawa Benjamin, Perentesis John P, Pommert Lauren

机构信息

Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

出版信息

Pediatr Blood Cancer. 2023 Apr;70(4):e30214. doi: 10.1002/pbc.30214. Epub 2023 Jan 24.

DOI:10.1002/pbc.30214

PMID:36694431

Abstract

Multiagent immunochemotherapy affords excellent outcomes in pediatric non-Hodgkin lymphoma (NHL); however, scarce data exist for patients unfit for intensive treatment. Rituximab, gemcitabine, and oxaliplatin (R-GemOx) is well tolerated and efficacious in elderly adults with NHL; however, its use has not been described in pediatrics. In this retrospective, single-center study, six children with mature B-cell NHL and significant comorbidities received anti-CD20 therapy with GemOx (rituximab or obinutuzumab or ofatumumab with gemcitabine and oxaliplatin [R/O-GemOx]). R/O-GemOx was well tolerated and resulted in complete response in two of three patients with newly diagnosed NHL and one of three patients with primary refractory NHL. R/O-GemOx is a viable treatment option for children with NHL who cannot tolerate intensive therapy.

摘要

多药联合免疫化疗在儿童非霍奇金淋巴瘤（NHL）中疗效显著；然而，针对不适合强化治疗的患者，相关数据却很匮乏。利妥昔单抗、吉西他滨和奥沙利铂（R-GemOx）在老年NHL患者中耐受性良好且疗效显著；然而，其在儿科中的应用尚未见报道。在这项回顾性单中心研究中，6例患有成熟B细胞NHL且伴有严重合并症的儿童接受了GemOx方案的抗CD20治疗（利妥昔单抗或奥滨尤妥珠单抗或奥法木单抗联合吉西他滨和奥沙利铂[R/O-GemOx]）。R/O-GemOx耐受性良好，在3例新诊断的NHL患者中有2例、3例原发性难治性NHL患者中有1例获得了完全缓解。R/O-GemOx是无法耐受强化治疗的NHL患儿的一种可行治疗选择。